
Athira Pharma, Inc. (ATHA)
$
6.75
-0.44 (-6.52%)
Key metrics
Financial statements
Free cash flow per share
-13.2724
Market cap
18.5 Million
Price to sales ratio
0
Debt to equity
0.0340
Current ratio
9.6968
Income quality
1.3876
Average inventory
0
ROE
-1.0706
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing small molecules aimed at restoring neuronal health and slowing neurodegradation. The company achieved a revenue of $0.00 indicating its niche market focus. Athira's lead product candidate, ATH-1017, is a blood-brain barrier-penetrating small molecule HGF/MET positive modulator currently undergoing LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for Alzheimer's disease treatment, as well as Phase 2 clinical trials for Parkinson's disease. In addition, the company has product candidates in the preclinical stage, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations, while also recording an income tax expense of $0.00 indicating its tax obligations. Furthermore, Athira Pharma recorded an operating income of -$100,902,000.00 reflecting its earnings from core operations, and earned an interest income of $3,962,000.00 showcasing its financial investments. Established in 2011 and headquartered in Bothell, Washington, Athira Pharma was formerly known as M3 Biotechnology, Inc., a name it adopted in April 2019. Athira Pharma's stock is affordable at $3.87 making it suitable for budget-conscious investors. The stock enjoys a high average trading volume of 1,056,070.00 indicating strong liquidity in the market. With a market capitalization of $26,621,237.00 the company is classified as a small-cap player, which allows for potential growth within the sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Athira belongs to the Healthcare sector, driving innovation and growth through its development of promising therapeutic candidates.
Analysts predict Athira Pharma, Inc. stock to fluctuate between $2.20 (low) and $8.36 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-01-09, Athira Pharma, Inc.'s market cap is $26,621,237, based on 3,943,887 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Athira Pharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Athira Pharma, Inc. (ATHA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATHA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Athira Pharma, Inc.'s last stock split was 1:10 on 2025-09-18.
Revenue: $0 | EPS: -$25.20 | Growth: -18.45%.
Visit https://www.athira.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $16.65 (2021-11-12) | All-time low: $0.22 (2025-04-08).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

accessnewswire.com
RC drilling underway at Excelsior Springs; Permits pending at Laird Lake WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / February 5, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada and its Laird Lake Project in Ontario. Mammoth Minerals Limited (ASX: M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest in the project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see press releases dated June 2, 2025, and August 22, 2025).

accessnewswire.com
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / February 5, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQB:SASKF)(FRA:X5U) is pleased to announce that it has closed approximately C$63 million in new financing to advance exploration at scale and development of its Angilak Project, Nunavut: further to its press releases dated January 13 and January 22, 2026, the Company has closed its private placement of USD$25 million (approximately C$34,130,000 million1) principal amount of unsecured convertible debentures (the "Debentures") of the Company (the "QRC Investment") with Queen's Road Capital Investment Ltd. ("QRC"); and further to its press release dated January 15, 2026, the Company has closed its best efforts brokered private placement of charity "flow-through" common shares of the Company ("FTShares", and the common shares of the Company, "Shares"), including a full exercise of the agent's option, with Canaccord Genuity Corp. and CIBC Capital Markets (together, the "Co-Lead Agents"), acting as co-lead agents and joint bookrunners, together with a syndicate of agents including Stifel Nicolaus Canada Inc., Haywood Securities Inc. and Paradigm Capital Inc. (together with the Co-Lead Agents, the "Agents") through the issuance of 28,186,500 FT Shares at a price per FT Share of C$1.02 for aggregate gross proceeds of C$28,750,230 (the "LIFE Offering").

accessnewswire.com
WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / January 19, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") would like to cordially invite existing and prospective investors to visit Booth #212 at the Vancouver Resource Investment Conference (VRIC) to be held at the Vancouver Convention Centre (1055 Canada Place, Vancouver) on Sunday, January 25 to Monday, January 26, 2026. About the Vancouver Resource Investment Conference: The Vancouver Resource Investment Conference has been the epicenter of junior mining investment in Canada for 25 years and attracts over 5,000 mining investors annually.

globenewswire.com
Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV:SASK) (FRA:X5U) (OTCQB:SASKF) (“ATHA” or the “Company”) announces today that it has entered into an agreement pursuant to which Canaccord Genuity Corp. and CIBC World Markets have agreed to act as co-lead agents and joint bookrunners, for and on behalf of a syndicate of agents (the “Agents”), in connection with a best efforts private placement of up to 24,510,000 flow-through shares of the Company (each, a “FT Share”) at a price of $1.02 per FT Share, for gross proceeds of up to $25,000,200. The Agents will also have the option, exercisable in whole or in part at any time prior to the closing of the Offering, to sell up to an additional 3,676,500 FT Shares.

accessnewswire.com
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 2, 2026 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") announces the grant of an aggregate of 10,150,000 incentive stock options ("Options") and 1,300,000 restricted share units ("RSUs") to certain eligible participants, including certain directors and officers of the Company, under the Company's equity incentive plan (the "Plan"). One-third of the Options shall vest on the date of issuance thereof, one-third of the Options shall vest on the six-month anniversary of the date of issuance thereof, and the remaining one-third of the Options shall vest on the twelve-month anniversary of the date of issuance thereof.

accessnewswire.com
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / December 19, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that, further to its news releases of November 17, November 24, December 9, and December 15, 2025, the Company has closed the third and final tranche of its private placement financing (the "Offering") and has received proceeds of CDN $502,002.98 through the issuance of 7,142,900 flow-through units (the "FT Units") at CDN $0.07 per FT Unit and 33,333 non-flow-through units (the "NFT Units") at CDN $0.06 per NFT Unit. A total of CDN $3,500,028.99 was raised in the Offering, of which CDN $2,727,526.03 was raised in the first tranche, CDN $270,499.98 in the second tranche and CDN $502,002.98 in the third tranche.

benzinga.com
Athira Pharma Inc. (NASDAQ: ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.

seekingalpha.com
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

geekwire.com
In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.

accessnewswire.com
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / December 15, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that, further to its news releases of November 17, November 24 and December 9, 2025, the Company has closed the second tranche of its private placement financing (the "Offering") and has received proceeds of CDN $270,499.98 through the issuance of 150,000 flow-through units (the "FT Units") at CDN $0.07 per FT Unit and 4,333,333 non-flow-through units (the "NFT Units") at CDN $0.06 per NFT Unit. An aggregate of CDN $2,727,526.03 was raised in the first tranche of the Offering.
See all news